Deletion of BCG Hip1 protease enhances dendritic cell and CD4 T cell responses
Open Access
- 28 December 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 103 (4) , 739-748
Abstract
Dendritic cells (DCs) play a key role in the generation of CD4 T cell responses to pathogens. Mycobacterium tuberculosis (Mtb) harbors immune evasion mechanisms that impair DC responses and prevent optimal CD4 T cell immunity. The vaccine strain Mycobacterium bovis Bacille Calmette‐Guérin (BCG) shares many of the immune evasion proteins utilized by Mtb, but the role of these proteins in DC and T cell responses elicited by BCG is poorly understood. We previously reported that the Mtb serine protease, Hip1, promotes sub‐optimal DC responses during infection. Here, we tested the hypothesis that BCG Hip1 modulates DC functions and prevents optimal antigen‐specific CD4 T cell responses that limit the immunogenicity of BCG. We generated a strain of BCG lacking hip1 (BCGΔhip1 ) and show that it has superior capacity to induce DC maturation and cytokine production compared with the parental BCG. Furthermore, BCGΔhip1‐infected DCs were more effective at driving the production of IFN‐γ and IL‐17 from antigen‐specific CD4 T cells in vitro. Mucosal transfer of BCGΔhip1‐infected DCs into mouse lungs induced robust CD4 T cell activation in vivo and generated antigen‐specific polyfunctional CD4 T cell responses in the lungs. Importantly, BCGΔhip1‐infected DCs enhanced control of pulmonary bacterial burden following Mtb aerosol challenge compared with the transfer of BCG‐infected DCs. These results reveal that BCG employs Hip1 to impair DC activation, leading to attenuated lung CD4 T cell responses with limited capacity to control Mtb burden after challenge.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health (5R01AI083366-05, 2R56AI083366-06A1)
- National Primate Center (RR000165)
- Georgia Research Alliance
- Emory University School of Medicine
- National Center for Advancing Translational Sciences (UL1TR000454)
This publication has 48 references indexed in Scilit:
- The Tuberculosis Vaccine Candidate Bacillus Calmette-Guérin ΔureC::hly Coexpressing Human Interleukin-7 or -18 Enhances Antigen-Specific T Cell Responses in MicePLOS ONE, 2013
- Recombinant BCG ΔureC hly+ Induces Superior Protection Over Parental BCG by Stimulating a Balanced Combination of Type 1 and Type 17 Cytokine ResponsesThe Journal of Infectious Diseases, 2011
- Relief from Zmp1-Mediated Arrest of Phagosome Maturation Is Associated with Facilitated Presentation and Enhanced Immunogenicity of Mycobacterial AntigensClinical and Vaccine Immunology, 2011
- Dendritic Cells in Chronic Mycobacterial Granulomas Restrict Local Anti-Bacterial T Cell Response in a Murine ModelPLOS ONE, 2010
- Differentiation of Effector CD4 T Cell PopulationsAnnual Review of Immunology, 2010
- A Liposome-Based Mycobacterial Vaccine Induces Potent Adult and Neonatal Multifunctional T Cells through the Exquisite Targeting of Dendritic CellsPLOS ONE, 2009
- Mycobacterium tuberculosis Prevents Inflammasome ActivationCell Host & Microbe, 2008
- Immunisation with BCG and recombinant MVA85A induces long‐lasting, polyfunctional Mycobacterium tuberculosis‐specific CD4+ memory T lymphocyte populationsEuropean Journal of Immunology, 2007
- Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectivenessThe Lancet, 2006
- Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosisNature Medicine, 2003